Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

NCT00603356 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: OSI-930 and erlotinib

Sponsor

Astellas Pharma Inc

Collaborators

[object Object]